EQS-News: Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios
EQS-News: Marinomed Biotech AG / Key word(s): Alliance
Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian
pharmaceutical company Aché Laboratórios
25.04.2024 / 07:45 CET/CEST
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian
pharmaceutical company Aché Laboratórios
• Marinomed will apply the Marinosolv solubilization technology to
improve target compounds with the goal of developing products with
differentiated pharmacological profiles
• The project covers the proof-of-concept evaluation and future
development of selected products with exclusivity rights for Aché in
Latin America
• Second long-term partnership for Marinomed’s Solv4U business area to
generate royalites after successful market entry
Korneuburg, Austria, 25 April 2024 – Marinomed Biotech AG (VSE:MARI)
announces the establishment of an R&D collaboration under its Solv4U
platform with Aché Laboratórios Farmaceuticos S.A., one of the largest and
most innovative pharmaceutical companies in Brazil. Aché is known for its
leadership in prescription medicines, and its commitment to developing
innovative solutions for unmet medical needs. Through its Solv4U
partnership program, Marinomed offers its proprietary Marinosolv
solubilization technology to customers from pharma and biotech to address
solubility and bioavailability issues and support the formulation
development of active pharmaceutical ingredients (APIs). The scope of the
collaboration is to assess the Marinosolv technology in selected molecules
with the aim of achieving products with improved pharmacological profiles,
enhanced solubility, and lower dosages. Aché will have exclusive rights to
apply the Marinosolv technology to the targeted compounds, which are
intended to be further developed and marketed as pharmaceutical products
under Aché’s trademarks in the LATAM region. After successful market
entry, Marinomed will benefit from royalties on sales of the products in
the Latin American growth market. The agreement also includes provisions
for both parties to exploit the potential of these products in ex-LATAM
territories, based on the successful completion of the R&D feasibility
stage.
Cornelia Siegl, Head of Solv4U, commented: “We are excited to embark on
this journey with Aché and look forward to the collaboration on this
Solv4U project with such an innovative partner. The conclusion of a
further long-term Solv4U partnership shows that low drug solubility and
bioavailability are still one of the biggest hurdles in drug development
and that innovative solutions like ours are urgently needed. The
Marinosolv technology has proven to be successfully applicable to a wide
range of pharmaceutical compounds not only in our own product development
but also in various partner projects.”
Andreas Grassauer, CEO of Marinomed, added: “Following the Solv4U
partnership with our Shanghai-based partner SPH Sine Pharmaceuticals last
year, the cooperation with Aché Laboratórios is another important
milestone in Marinosolv’s success story. We look forward to working
closely with Aché for the next years in the dynamic growth market of Latin
America. Technology partnerships like that accelerate the transition from
research to commercial application. We are excited to further expand our
Solv4U business in the future and to improve the efficacy of active
pharmaceutical compounds with our innovative Marinosolv technology.”
Hatylas Azevedo, R&D Director of Aché, said: “We’re excited to collaborate
with Marinomed to investigate the potential of the Marinosolv technology
on increasing pharmacokinetic and pharmacodynamic properties of first-line
treatments for prevalent diseases. Aché’s experience in the R&D and
commercialization of innovative medicines will teamwork with Marinomed’s
know-how and cutting-edge technology for developing differentiated
products that address important unmet medical needs.”
About Aché Laboratórios Farmaceuticos S.A.
Aché Laboratórios Farmaceuticos S.A. is a reputable Brazilian
pharmaceutical company established 57 years ago. Renowned in the fields of
prescription and specialty medicines, it stands as one of Brazil’s largest
and most innovative pharmaceutical companies. Operating from five
industrial facilities, Aché manufactures a wide array of pharmaceuticals,
including solids, liquids, semi-solids, parenteral drugs, antibiotics, and
contraceptives. The company boasts a workforce of around 5,000 employees
and maintains a portfolio comprising over 300 branded products spanning
various therapeutic domains, being the leader of Respiratory care in
Brazil. Recognized by its innovation and quality, Aché has been recognized
as the most innovative company in the pharmaceutical sector. Nearly 350
personnel are dedicated to R&D activities such as drug discovery,
pharmaceutical sciences, preclinical and clinical development, alongside a
business development unit focused on fostering partnerships. In recent
years, Aché has introduced numerous groundbreaking products and forged
global collaborations with prominent biotech and pharmaceutical firms,
aiming to pioneer novel compounds, fixed-dose combinations and innovative
dosage forms and technologies for addressing diseases with substantial
unmet medical needs.
About Marinosolv®:
Marinosolv® is an innovative technology platform that enables the
solubilization and enhances the bioavailability of small molecules and
peptides that are hardly soluble in aqueous formulations. Consequently,
new treatments of a multitude of diseases can be envisaged. The use of the
Marinosolv® technology can facilitate efficient drug delivery with a low
systemic off-target activity. Existing drugs and off-patent active
ingredients can be improved and re-patented as part of new formulations
using Marinosolv®. Under the brand Solv4U, Marinomed provides Marinosolv®
formulation development in technology partnerships for active ingredients
at all stages of drug discovery and for lifecycle extension. For more
information on Marinosolv® or Solv4U, please visit
[1] https://www.solv4u.com. Scientific publications on Marinosolv® can be
accessed in the “Immunology” tabs at
[2] https://www.marinomed.com/en/news/scientific-publications.
About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline and globally marketed therapeutics. The
Company develops innovative patent-protected products in the therapeutic
areas immunology and virology based on the platform Marinosolv® and the
virus-blocking activity of Carragelose®. The Marinosolv® technology
improves the solubility and bioavailability of hardly soluble compounds
and is used to develop new therapeutics for autoreactive immune disorders.
The virology segment includes Carragelose®-based over-the-counter (OTC)
products to prevent and treat respiratory viral infections that are
partnered in more than 40 countries. The Company is headquartered in
Korneuburg, Austria, and is listed on the prime market of the Vienna Stock
Exchange (VSE:MARI). For further information, please visit:
[3] https://www.marinomed.com.
For further inquiries contact:
Marinomed Biotech AG International Media Contact
PR & IR: Lucia Ziegler Metrum Communications: Eva Ruppnig
T: +43 2262 90300 158 T: +43 664 4065744
E-Mail: [4]pr@marinomed.com E-Mail: [6]marinomed@metrum.at
E-Mail: [5]ir@marinomed.com
Disclaimer
This press release contains forward-looking statements, which are based on
current views, expectations and projections of the management of Marinomed
Biotech AG about future events. These forward-looking statements are
subject to risks, uncertainties and assumptions that could cause actual
results, performance or events to differ materially from those described
in, or expressed or implied by, such statements. The current views,
expectations and projections of the management of Marinomed Biotech AG may
be identified by the context of such statements or words such as
“anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
and “target”. Forward-looking statements are only valid as of the date
they are made and Marinomed Biotech AG does not assume any obligation to
update, review or revise any forward-looking statements contained in this
press release whether as a result of new information, future developments
or otherwise. Marinomed, Marinosolv® and Carragelose® are registered
trademarks of Marinomed Biotech AG. These trademarks may be owned or
licensed in select locations only.
══════════════════════════════════════════════════════════════════════════
25.04.2024 CET/CEST This Corporate News was distributed by EQS Group AG.
www.eqs.com
══════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 1888693
End of News EQS News Service
1888693 25.04.2024 CET/CEST
References
Visible links
1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=bd2eeb8ec4c89acd0f1d74110ad9cc92&application_id=1888693&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
2. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=22703f0463e8f6df4d84a973309eef6c&application_id=1888693&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
3. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b364e041c58da1aeff9758a10a9b0152&application_id=1888693&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
4. pr@marinomed.com
5. ir@marinomed.com
6. marinomed@metrum.at
OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender